Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Data From the L-MIND Trial

August 2nd 2021

Greg Nowakowski, MD [Mayo Clinic, Rochester, Minnesota], reviews the data from the L-MIND trial of tafasitamab and lenalidomide for transplant-ineligible patients with R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma).

FDA Grants Fast Track Status to Eryaspase for Hypersensitive Acute Lymphocytic Leukemia

July 30th 2021

The FDA has granted a fast track designation to eryaspase for use as a potential therapeutic option in patients with acute lymphocytic leukemia who have developed hypersensitivity reactions to Escherichia coli–derived pegylated asparaginase.

Frontline Therapy for Patients With CLL: Testing and Risk Classification

July 30th 2021

A review of how frontline therapy selection for patients with CLL is informed by molecular testing, staging, and risk stratification amidst a multitude of other disease factors.

ESA Use in the Treatment of MDS

July 30th 2021

The panel of experts discusses considerations necessary when recommending treatment with erythropoiesis-stimulating agents in patients with myelodysplastic syndrome.

Impact of Targeted Therapy in CLL

July 30th 2021

Expert insight on the impact that targeted therapies have had on the frontline treatment landscape of chronic lymphocytic leukemia.

Guidelines for the Treatment of MDS

July 30th 2021

Rami Komrokji, MD, discusses his approach to treatment in patients with myelodysplastic syndrome, while being mindful of recommended guidelines.

Second-Generation FLT3 Inhibitors for Acute Myeloid Leukemia

July 29th 2021

A panel of thought leaders in AML examines single-agent and combination-based approaches using the second-generation FLT3 inhibitors gilteritinib, quizartinib, and crenolanib.

The Role of FLT3 Inhibitors for Treatment of AML

July 29th 2021

Experts in hematologic malignancies provide key insights into the use of FLT3 inhibitors and discuss whether it is possible to predict patients who may benefit from midostaurin + chemotherapy.

Enasidenib Elicits Clinical Efficacy in High-Risk, IDH2-Mutated MDS

July 29th 2021

The IDH2 inhibitor enasidenib demonstrated promising efficacy in combination with azacitidine and as a single agent in patients with high-risk, IDH2-mutated myelodysplastic syndrome.

Approaches to Treatment of Ph+ ALL

July 27th 2021

A discussion on how to approach the treatment of a pediatric or AYA (adolescent and young adult) patient with ALL (acute lymphoblastic leukemia) who is Philadelphia chromosome positive (Ph+ALL).

Risk Assessment in ALL

July 27th 2021

Ibrahim Aldoss, MD, and James K. McCloskey, MD, share their thoughts on different stratification measures used to assess risk in pediatric, adolescent, and young adult patients newly diagnosed with ALL.

Recommendations for Second-Line Therapy in DLBCL

July 26th 2021

Key opinion leaders discuss recommended second-line treatment options for patients with DLBCL.

Managing Relapsed DLBCL

July 26th 2021

Cyrus Khan, MD, reviews the management of DLBCL after relapse on frontline therapy.

Brentuximab Vedotin Plus Chemo Shows Strong Activity in Early-Stage Hodgkin Lymphoma

July 25th 2021

The combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine with and without consolidative radiotherapy was found to have strong efficacy and favorable tolerability in patients with early-stage, unfavorable-risk, Hodgkin lymphoma.

Individualized Treatment for MDS

July 23rd 2021

The panel of leukemia experts highlight the importance of individualized treatments for patients with myelodysplastic syndrome.

Staging Models in Diagnosis and Risk Assessment of MDS

July 23rd 2021

Rami Komrokji, MD, and Gail Roboz, MD, discuss the importance of staging models in the diagnosis and routine assessment of patients with myelodysplastic syndrome.

Siddiqi Spotlights Latest Data on Optimization of Therapy in Hematologic Malignancies

July 23rd 2021

Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.

Molecular Testing Turnaround Time and Treatment Delay

July 22nd 2021

Key opinion leaders in acute myeloid leukemia reflect on challenges associated with molecular testing by commenting on potential treatment delay from the long turnaround time (TAT) of next-generation sequencing.

Transplant-Associated Thrombotic Microangiopathy: New Insights, Emerging Treatments

July 22nd 2021

An expert of panelists provide an overview of TA-TMA, including findings that raise suspicion of this complication, strategies they use for making the diagnosis, and how they intervene given limited treatment options.

Molecular Testing for Acute Myeloid Leukemia

July 22nd 2021

Mark Levis, MD, PhD, leads a panel of experts in a discussion on factors to consider when ordering molecular testing for newly diagnosed and relapsed/refractory acute myeloid leukemia.